Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach slowdown may delay heart attack drug action

NCT ID NCT02251249

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This completed study looked at whether stomach emptying is slower during a heart attack, which could delay the absorption of crucial antiplatelet drugs. Researchers measured paracetamol levels in the blood every 15 minutes in 23 participants to track stomach emptying. The goal was to understand why some patients don't respond quickly to treatment, potentially leading to better care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
paracetamol, prasugrel, ticagrelor
What this could lead to
If successful, this could help doctors understand why some heart attack patients don't respond quickly to antiplatelet drugs, potentially leading to better treatment strategies.
What could go wrong
This is a small, early-phase study with only 23 participants, so results may not apply to all patients. It is observational in nature and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

23 people

The number who actually took part.

Started

Dec 2014

Finished

Sep 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years weighing between 65 and 85 Kg * Referred for STEMI within 6 hours from beginning of chest pain or stable coronary artery disease requiring a loading dose of Prasugrel or Ticagrelor according to the international recommendations. * No previous treatment with Clopidogrel, Prasugrel or Ticagrelor. * Patient fasting for at least 6 hours. * Affiliate or receiving a social security system. * Written informed consent. Exclusion Criteria: * Allergy or contraindication to paracetamol, Prasugrel or Ticagrelor * Paracetamol ingestion in the previous 48 hours * Patient treated with drugs supposed to alter gastric emptying times (calcium antagonists, Alimentary tract treatments, opioid analgesics, tricyclic antidepressants, antibiotics). * Conditions or pathologies supposed to alter gastric emptying times (Thyroid dysfunction, chronic renal failure, Parkinson's disease, scleroderma, amyloidosis, any gastrointestinal disease, any not cured malignancy, and any advanced psychiatric or neurological disease). * Presence of vomiting * Cardiogenic shock, ventricular arrhythmia or resuscitated cardiac arrest * Hepatic insufficiency * Severe respiratory disease * Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute phase of myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction coronary artery disorder gastroparesis ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute phase of myocardial infarction Impairment of gastric emptying

Contacts and locations

Locations

  • CHU de Bordeaux - Hôpital du Haut Lévèque

    Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.